References
- Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640–1645.doi:10.1161/CIRCULATIONAHA.109.192644.
- Ridker Paul M, Wilson Peter WF, Grundy Scott M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109(23):2818–2825. doi:10.1161/01.CIR.0000132467.45278.59.
- Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel PJ, Jialal I. CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol. 2008;129(5):815–822. doi:10.1309/RN84K51B2JJY1Y0B.
- Jialal I, Jialal G, Adams-Huet B, Ramakrishnan N. Neutrophil and monocyte ratios to high-density lipoprotein-cholesterol and adiponectin as biomarkers of nascent metabolic syndrome. Horm Mol Biol Clin Investig. March 2020. doi:10.1515/hmbci-2019-0070.
- Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010;21(11):660–667. doi:10.1016/j.tem.2010.08.001.
- Helfer G, Wu Q-F. Chemerin: a multifaceted adipokine involved in metabolic disorders. J Endocrinol. 2018;238(2):R79–R94. doi:10.1530/JOE-18-0174.
- Chu SH, Lee MK, Ahn KY, et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS ONE. 2012;7(4):e34710.doi:10.1371/journal.pone.0034710.
- Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab. 2013;98(3):E514–517. doi:10.1210/jc.2012-3673.
- Jialal I, Devaraj S, Adams-Huet B, Chen X, Kaur H. Increased cellular and circulating biomarkers of oxidative stress in nascent metabolic syndrome. J Clin Endocrinol Metab. 2012;97(10):E1844–1850. doi:10.1210/jc.2012-2498.
- Adams-Huet B, Devaraj S, Siegel D, Jialal I. Increased adipose tissue insulin resistance in metabolic syndrome: relationship to circulating adipokines. Metab Syndr Relat Disord. 2014;12:503–507.
- Pirillo A, Catapano AL, Norata GD. Biological Consequences of Dysfunctional HDL. Curr Med Chem. 2019;26(9):1644–1664. doi:10.2174/0929867325666180530110543.
- Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia. 2012;55(9):2319–2326. doi:10.1007/s00125-012-2598-x.
- Jialal I, Devaraj S. Subcutaneous adipose tissue biology in metabolic syndrome. Horm Mol Biol Clin Investig. 2018;33:1. doi:10.1515/hmbci-2017-0074.
- Li Y, Shi B, Li S. Association between serum chemerin concentrations and clinical indices in obesity and metabolic syndrome: a meta-analysis. Plos One. 2014;9:e113915.
- Hashemi M, Rezaei H, Eskandari-Nasab E, Kaykhaei MA, Zakeri Z, Taheri M. Association between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome, a preliminary report. Gene. 2012;510(2):113–117. doi:10.1016/j.gene.2012.08.048.
- Mehanna E, Mesbah N, Ghattas M, et al. Association of chemerin Rs 17173608 and Vaspin Rs 2236242 gene polymorphisms with metabolic syndrome in Egyptian women. Endocr Res. 2016;41:43–48.